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Jenifer R. Lightdale,1,2 Adrienne G. Randolph,2,3 Chau M. Tran,4 Hongyu Jiang,2,4
Andrea Colon,5 Kathleen Houlahan,6,7 Amy Billet,2,8,9 Steven Sloan,2,9
Leslie E. Lehmann2,7,8A 2008 randomized trial of critically ill, but stable, children reported the safety of transfusing red blood cells
at a hemoglobin threshold of 7 g/dL. In 2009, we adopted the same transfusion criteria in our hematopoietic
stem cell transplantation patients. Regression modeling was used to compare data obtained during primary
admission for hematopoietic stem cell transplantation in calendar years before and after our practice change.
Sixty-six patients admitted in the preintervention year were compared with 75 postintervention. Pre- and
postpatients were similar in diagnoses and type of transplantations. Postintervention, median hemoglobin
pretransfusion significantly decreased from 8.8 g/dL to 6.8 g/dL (P\.0001). In addition, transfused red blood
cell units received by patients dropped from 4 (interquartile range [IQR] 3, 8) to 3 (IQR, 2, 5), (P5.002), and
number of transfusion days per patients decreased from 4 (IQR, 2,5) to 3 (IQR, 2, 5), (P5.01). Therewere no
differences in length of stay, time to engraftment, or 100-day mortality. Median blood product charges per
patient significantly decreased ($3,624 [IQR, $2,265, $6,040] to $2,185 [IQR, $1,812, $3,997], P 5 .004).
Our initial experience suggests that implementation of a conservative transfusion strategy in otherwise stable
children undergoing hematopoietic stem cell transplantation appears safe and lowers transfusion exposures.
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6/j.bbmt.2011.10.043for patients undergoing myeloablative hematopoetic
stem cell transplantation (HSCT) [1]. Although such
transfusions are generally well tolerated, there are
associated short- and long-term risks. Acutely, patients
are susceptible to volume overload and transfusion re-
actions including rare but serious complications such as
anaphylaxis, viral transmission, and transfusion-related
lung injury [2]; long-term sequelae include transfusion-
associated immune compromise [3] and iron overload
[4]. Blood products are also a limited and expensive
healthcare resource. Because of the potential for
harm and associated cost, transfusion exposures should
beminimized. In recent years, conservative RBC trans-
fusion strategies have been implemented in a variety of
populations including pediatric intensive care unit pa-
tients, premature newborns, and infants undergoing
reparative cardiac surgery [2,5-7]. Although patients
undergoing HSCT represent one of the most heavily
transfused groups in pediatrics, there have been no
studies of the impact of using conservative thresholds
for transfusions in these children.
Several well-controlled studies have shown that
limiting blood transfusions in critically ill, but stable
patient populations does not affect morbidity and813
814 Biol Blood Marrow Transplant 18:813-817, 2012J. R. Lightdale et al.mortality [2,5,8,9]. Most of these studies
excluded critically ill and unstable patients who were
bleeding, severely hypoxic, and/or in shock requiring
vasopressors. A 1999 multicenter randomized
controlled trial in critically ill adults found a
restrictive strategy of maintaining hemoglobin (Hgb)
concentrations between 7 and 9 g/dL resulted in a
trend toward decreased mortality when compared
with more liberal transfusion strategies designed to
maintain a hemoglobin level .10 g/dL, excepting in
patients with active coronary ischemic syndromes [9].
In 2007, a multicenter noninferiority randomized trial
was conducted in children in the pediatric intensive
care unit comparing outcomes using a conservative he-
moglobin threshold of 7 g/dL with that of 9.5 g/dL.
The results suggest that use of the lower hemoglobin
threshold reduced tranfusions by 44% without affect-
ing a number of clinical outcomes, including rates of
organ failure, ventilator days, and mortality [5].
Before 2009, patients in our HSCT unit received
routine RBC transfusions when hemoglobin levels
were\9 g/dL. In February 2009, following a month-
long review of the pediatric critical care literature and
discussion among physician and nursing staff, we im-
plemented apractice change touse a routine transfusion
hemoglobin threshold of\7 g/dL in HSCT patients
who were not clinically unstable. We subsequently
performed the following pre/postanalysis to assess the
impact of changing our transfusion strategy in children
undergoingHSCTat our institution.Wehypothesized
that adopting a more conservative transfusion strategy
in this patient populationwould lead to less use of blood
products and decreased healthcare charges without
negatively affecting patient outcomes.METHODS
As part of a quality improvement initiative, we
compared census and transfusion data for all patients
admitted for HSCT to our unit during the calendar
year before and for 1 year after a written change in
transfusion protocol dated 2/10/2009. Before the
practice change, our standard operating procedure
stipulated that clinically stable patients undergoing
transplantation should be transfusedwhen hemoglobin
levels were\9 g/dL. Subsequently, a revised standard
operating procedure recommended limiting routine
transfusions for hemoglobin levels\7 g/dL.We chose
two 12-month study periods: 1/1/2008-12/31/2008
before the change, allowed a 2-month washout period,
and compared 3/1/09-2/28/10 following practice
change. Results of our analysis were extensively pre-
sented internally within our institution. We also dis-
cussed any human subjects review requirements with
our hospital’s institutional review board in preparation
for dissemination of our findings externally. Per the
policy at our institution, because this was implementedas a quality improvement initiative and not a research
project, our institutional review board stated that it
was exempt from and declined the opportunity for
full review.
We included patients admitted to the HSCT unit
at our hospital for a first transplantation during the
study periods, excluding patients who had a second
transplantation even if it was part of their original
transplantation protocol and patients admitted for
other indications such as suspected sepsis. We exam-
ined the entire length of stay for each patient accord-
ing to HSCT database maintained for the purposes
of FACT (Foundation for the Accreditation of Cel-
lular Therapy; www.factwebsite.org) accreditation.
Transplantation-related deaths, in particular, were
reviewed to determine any possible relationship to
transfusion practice.
All specific transfusion decisions for individual
patients during both study periods were made at the
discretion of physician attendings. Blood product
orders were placed by either hematology-oncology
fellows or by pediatric housestaff rotating through
the unit. Transfusions in this pediatric population
were generally ordered on a mL/kg basis, and there
was no change in the practice of ordering transfusions
during the study period.
Data from both periods were collected and ana-
lyzed using the methods established by the PRU-
DENT (Patient Resource Use—Determination of
Effective and Necessary Targets) project team at Chil-
dren’s Hospital Boston. Data abstracted from medical
records included patient demographics, type of blood
products transfused, the number and dates of transfu-
sions, the temporal relationship between transfusions
and mortality, and patient hemoglobin levels both
before and after transfusion. Data obtained from our
institution’s blood bank registry included dates and
numbers of units of blood products transfused. Addi-
tional data collected from our HSCT database in-
cluded primary diagnosis, date of transplantation,
type of transplantation (autologous versus sibling do-
nor versus matched unrelated donor), time to engraft-
ment, intensive care unit days, and 100-day mortality.
We also collected data on patient healthcare charges at
our institution from the Pediatric Health Information
System, an administrative database affiliated with the
Child Health Corporation of America (Shawnee
Mission, KS), a business alliance of children’s hospitals
that contains inpatient, emergency department, ambu-
latory surgery, and observation data.
Statistical Analysis
Categoric patient characteristics and outcomes
were reported as counts and percentages, and were
compared by c2 or Fisher exact test between groups.
Continuous and count data were summarized using
median and interquartiles ranges (IQR), and were
Table 1. Baseline Characteristics of HSCT Patients Trans-
fused Pre- and Postpolicy Change in Transfusion Hemoglobin
Threshold from <9 g/dL to <7 g/dL
Patient Characteristics
Prechange
(n 5 66)
Postchange
(n 5 75) P Value
Age (years), median (IQR) 6 (2, 12.3) 6 (3, 13) .83
Male sex, n (%) 29 (43.9%) 55 (73.3%) .004
White race, n (%)a 42 (77.8%) 50 (76.9%) .7
Diagnosis, n (%): .31
Hematologic malignancies 34 (51.6%) 28 (37.3%)
Lymphoma and solid tumor 22 (33.3%) 28 (37.3%)
Nonmalignant hematology 6 (9.1%) 12 (16.0%)
Neuroblastoma 4 (6.1%) 7 (9.3%)
Type of transplantation, n (%) .87
Auto 22 (33.3%) 26 (34.7%)
Sibling 13 (19.7%) 15 (20.0%)
BM-UR donor 31 (47.0%) 30 (40.0%)
Other family 0 (0%) 2 (2.7%)
UR cord 0 (0%) 2 (2.7%)
UR indicates unrelated.
aThe percentages of ‘‘White race’’ were calculated among those who
reported race, which were 54 and 65, respectively, in the pre- and post-
intervention periods.
Table 2. Percentage of Transfusion Days by Lowest Hemo-
globin Levels Prepractice Change (01/01/08-12/31/08) versus
Postpractice Change (03/01/09-02/28/09)
Preintervention
(n 5 243)
Postintervention
(n 5 286)
Transfused at 6.9 and below 2.1% 61.7%
Transfused between 7.0 and 7.3 1.7% 13.2%
Transfused between 7.4 and 7.5 2.1% 6.2%
Transfused between 7.6 and 7.9 4.5% 7.0%
Transfused at 8 and above 89.5% 11.9%
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All tests were two-sided at .05 significance level. Uni-
variate Poisson regression models were used to inves-
tigate risk factors for higher blood product use (as
measured by total transfusion days for each patient).
Multivariate Poisson regression model was used to
evaluate the effect from change of transfusion practice
on blood product use adjusting for significant risk fac-
tors. A box-plot was used to display the change in
median and IQR of the lowest pretransfusion Hgb
level that led to transfusion decision before and after
the practice change. Lowest Hgb levels were also
placed into five categories (#6.9, 7.0-7.3, 7.4-7.5,
7.6-7.9, $8.0 g/dL) with the pre- and postdistribu-
tions displayed graphically.RESULTS
A total of 66 patients admitted for HSCT in the
preintervention year were compared with 75 patientsFigure 1. Median lowest hemoglobin value (g/dL) prior to patient
transfusion day.admitted in the postintervention measurement period.
As shown in Table 1, patients had similar demo-
graphic, diagnostic, and transplantation characteristics
in both study periods, except there were more males in
the postintervention period.
Figure 1 shows a significant difference in the distri-
bution of lowest hemoglobin level before transfusion
between the two study periods. The median hemoglo-
bin level dropped from 8.8 g/dL (IQR, 8.4,9.2) to 6.8
g/dL (IQR, 6.5,7.4). Table 2 shows that 89.5% of
transfusions were given at a hemoglobin level of 8.0
g/dL or higher in the preintervention period, and
this percentage dropped to 12% in the postinterven-
tion period. In addition, the proportion of transfusions
based on an Hgb level 6.9 g/dL or less increased from
2% in the prepolicy change period to 62% in the post-
period.
Table 3 summarizesmeasures of blood product use
before and after our change in transfusion practice. As
expected, over 96% of the study patients received at
least one RBC transfusion in both study periods. Al-
though the postintervention period included more pa-
tients, the total transfused units were 22% less in the
postintervention period (307 units) compared with
the prepractice change period (392 units), and the total
number of days that patients were exposed to a transfu-
sion (transfusion days) was 15% less (243 days in the
postperiod versus 286 days in the preperiod). There
was a significant reduction in the median number of
transfused units per patient (4 units in the preperiod
versus 3 units in the postperiod; P 5 .002) and alsoTable 3. Comparison of CHB Bone Marrow Transplantation
Transfusion Practice between Pre- and Postintervention
Periods
Outcome
Preintervention
(1/1/08-12/31/08)
(N 5 66)
Postintervention
(3/1/09-2/28/10)
(N 5 75) P Value
Patients transfused, n (%) 65 (98.5%) 72 (96%) .38
Total RBC transfusion
units per study period
392 307
RBC transfusion units per
patient, median (IQR)
4 (3,8) 3 (2,5) .002
Total transfusion daysa per
study period
286 243
Transfusion days per
patient, median (IQR)
4 (2,5) 3 (2,5) .01
aTransfusion day is defined as a day in which a patient received at least 1
RBC unit.
Table 4. Comparison of CHB Bone Marrow Transplantation Patient Outcomes between Pre- and Postintervention Periods
Outcome
Preintervention (1/1/08-12/31/08)
(N 5 66)
Postintervention (3/1/09-2/28/10)
(N 5 75) P Value
Time to engraftment (days), median (IQR) 20 (12, 25) 18 (12,24) .71
Length of stay (days), median (IQR) 37(30, 46) 37 (29, 52) .69
100-day mortality (days), n (%): 17 (25.8%) 13 (17.3%) .22
Relapse related 9 (13.6%) 6 (8.0%)
Transplantation related 8 (12.1%) 7 (9.3%)
Transfusion-related charges, median (IQR) $3,624 ($2,265, $6,040) $2,185 ($1,812, $3,997) .004
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(4 days in the preperiod versus 3 days in the postperiod;
P 5 .01).
Univariate Poisson regression analysis revealed that
postpractice change, older age, undergoing autologous
transplantation, related allo-donor transplantations, as
well as diagnoses of lymphoma or other solid tumor
diagnosis were characteristics that were significantly as-
sociated with fewer transfusion days per patient.
Regression analysis did not find sex or race to be signif-
icant predictors of blood product use. In the multivari-
ate Poisson regression model, only transplantation
during the postpractice change period, age, and lym-
phoma/solid tumor diagnosis remained significant. In
allmodels, thepostpractice indicator variablehada con-
sistent coefficient estimate of about20.3 indicating the
average ratio of transfusion days in the postperiod over
preperiod is exp(20.3) 5 0.74. Thus, adopting a prac-
tice change reduced the number of transfusion days by
26% (adjusted P value5 .002).
Analysis of patient outcomes showed no differences
in length of stay, time to neutrophil engraftment, or
100-day mortality from relapse or transplantation
(Table 4). Specific causes of transplantation-related
deaths in the prepractice change group included infec-
tion (n 5 2); multiorgan system failure, no discernable
cause (two); graft-versus-host disease (GVHD) (two);
veno-occlusive disorder (one); and cardiac failure in a
single patient with prestem cell transplantation cardiac
dysfunction from adriamycin. Specific causes of
transplantation-related deaths in the postpractice
change group included multiorgan system failure, no
discernable cause (four); GVHD (one); and respiratory
failure (two).Median bloodproduct-related charges per
patientwere significantly lower (P5 .004) in the postin-
tervention period ($2,185 [IQR $1,812, $3,997] com-
pared with the preintervention period [$3,624]
[$2,265, $6,040] (P5 .004).DISCUSSION
Because of bone marrow ablation, RBC transfu-
sions are one of the most common supportive care in-
terventions in HSCT patients [1]. Implementing
a conservative red blood cell transfusion threshold
(\7 g/dL) in our in HSCT patients led to fewer trans-
fusions and lower transfusion-related costs, withoutaffecting either transplantation- or relapse-related
mortality, length of stay, or time to neutrophil engraft-
ment. Review of all transplantation-related deaths, in
particular, suggested that none was related to transfu-
sion practices in either time period. Although the
change in our protocol did not reduce the number of
patients who were exposed to at least one transfusion,
children treated with the conservative strategy re-
ceived less absolute numbers of RBC units and were
exposed to transfusions on fewer days, theoretically
decreasing risks associated with multiple donors,
such as viral transmission. It is possible that imple-
menting our threshold may have reduced median
blood product-related charges by more than $1,500,
because we did not consider nursing costs.
Our study identified younger age and unrelated
donor transplant as independent predictors of blood
transfusions. Younger patients have smaller body sizes
and less total blood volume than older populations [6].
For example, a 5-kg child has a blood volume of
approximately 400 mL, in comparison to the typical
adult volume of 5 L. Thus, younger children have less
reserve before crossing hemoglobin thresholds and
may be more vulnerable to iatrogenic anemia caused
by routine blood drawing during HSCT [2,6]. Patients
undergoing autologous transplantations are generally
healthier than patients who are the recipients of an
unrelated donor transplantation. In turn, the latter may
be more prone to complications, including infections,
bleeding, and GVHD that may make anemia less well
tolerated.
Transfusion decision making has been recognized
as an important target for healthcare resource modifi-
cation at the national level for over 20 years [10].
Transfusion practices are known to vary widely (up
to two-fold) between institutions and generally cannot
be attributed to patient or procedure factors [11].
Instead, it is generally accepted that transfusion prac-
tices are strongly influenced by local norms, which in
turn are predicated on the biases of individual clini-
cians. Encouraging the conservative use of RBCs,
a scarce, expensive, and vital healthcare resource,
may represent a prime paradigm for engaging physi-
cians in a national movement to reduce unwarranted
practice variation.
There are a number of limitations to our evalua-
tion of RBC utilization analysis. In particular, this
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analysis of annual census experiences before and after
a policy change. In turn, we did not perform an a priori
power calculation and may be limited in our ability to
interpret differences in outcomes. Our results may also
be vulnerable to confounding, despite our assumption
that there were no major institutional changes during
the two studied periods and the patient groups were
not significantly different. Although we did find an
increased proportion of females in the prepractice
change period, we have assumed this to be random.
Multivariate analysis was used to confirm that patient
sex was not a predictor of blood product use. We
note that we know little about long-term follow-up
of these patients, including whether a decrease in
transfusion exposure during the acute transplantation
period can affect lifelong risk of infection, antibody
production, or iron overload. As a final important lim-
itation, health-related quality of life was not assessed.
Future studies are required to provide a long-term
view on the potential for both positive and negative
impacts of conservative transfusion policies in this
high-acuity population.
Nevertheless, the results of our study suggest that
evidenced-based standardized transfusion criteria can
be powerful tools for reducing the use of RBCs in chil-
dren undergoing HSCT. In turn, children undergoing
HSCT with a conservative transfusion strategy may
be less at risk for acute and long-term sequelae of
receiving RBCs, including less risk for rare serious
transfusion-related events and viral transmission, as
well as infusion reactions and cumulative iron over-
load. They may also be less exposed to potentially im-
mune suppressive effects of transfusions [5]. Our study
also suggests that transfusion guidelines devised in
intensive care settings that use a hemoglobin target
of 7 g/dL may be safely extrapolated to patients in
transplantation units and that implementation of
such a conservative transfusion threshold inHSCTpa-
tients appears to be cost effective. Further, multicenter
studies are required to fully evaluate the safety of this
practice as well as to comprehensively assess its impact
on the provision of high-value, high-quality care in
pediatric HSCT units.
ACKNOWLEDGMENTS
The authors acknowledge support for this project
from the following organizations at Children’s Hospi-
tal Boston: the Physician’s Organization; the Transfu-
sion Committee, the Department of Laboratory
Medicine; the Information Systems Databases (ISD)
team; the Program for Patient Safety and Quality
(PPSQ) and the Clinical Research Program. We also
thank the following individuals for their assistance:
Maureen A. Beaton, MT(ASCP)BB, CQA(ASQ);
Patricia A. Branowicki, MS, RN, NEA-BC; LisaMorrissey, RN; and Erica P. Louras. Our project
was funded through the Physician’s Organization at
Children’s Hospital Boston.
Financial disclosure: The authors have nothing to
disclose.AUTHORSHIP STATEMENT
J.R. Lightdale designed the research and data col-
lection forms, analyzed data, wrote the article; A. G.
Randolph designed research, analyzed data, revised
the article; C.M. Tran performed data collection and
data analysis, and designed the figures; H. Jiang per-
formed data analysis; A. Colon designed research,
aided in data collection, and interpreted the data; K.
Houlahan designed research; A. Billet designed
research and interpreted the data; S. Sloan designed
research and interpreted the data; L.E. Lehmann
designed research, aided in data collection, interpreted
data, and revised the manuscript.REFERENCES
1. Gajewski JL, Johnson VV, SandLer SG, Sayegh A, Klumpp TR.
A review of transfusion practice before, during, and after hema-
topoietic progenitor cell transplantation. Blood. 2008;112:
3036-3047.
2. Bateman ST, Lacroix J, Boven K, et al. Anemia, blood loss, and
blood transfusions in North American children in the intensive
care unit. Am J Respir Crit Care Med. 2008;178:26-33.
3. Fraser GA, Walker II. Cytomegalovirus prophylaxis and treat-
ment after hematopoietic stem cell transplantation in Canada:
a description of current practices and comparison with Centers
for Disease Control/Infectious Diseases Society of America/
American Society for Blood andMarrowTransplantation guide-
line recommendations. Biol Blood Marrow Transplant. 2004;10:
287-297.
4. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow trans-
plantation in patients with thalassemia.N Engl J Med. 1990;322:
417-421.
5. Lacroix J, Hebert PC,Hutchison JS, et al. Transfusion strategies
for patients in pediatric intensive care units.NEngl J Med. 2007;
356:1609-1619.
6. RingerSA,RichardsonDK,SacherRA,KeszlerM,ChurchillWH.
Variations in transfusion practice in neonatal intensive care.Pediat-
rics. 1998;101:194-200.
7. KippsAK,WypijD,ThiagarajanRR, BachaEA,Newburger JW.
Blood transfusion is associated with prolonged duration of
mechanical ventilation in infants undergoing reparative cardiac
surgery. Pediatr Crit Care Med. 2011;12:52-56.
8. Bell EF, Strauss RG,Widness JA, et al. Randomized trial of lib-
eral versus restrictive guidelines for red blood cell transfusion in
preterm infants. Pediatrics. 2005;115:1685-1691.
9. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, ran-
domized, controlled clinical trial of transfusion requirements in
critical care. Transfusion Requirements in Critical Care Investi-
gators, Canadian Critical Care Trials Group. N Engl J Med.
1999;340:409-417.
10. Audet AM, Goodnough LT, Parvin CA. Evaluating the appro-
priateness of red blood cell transfusions: the limitations of retro-
spective medical record reviews. Int J Qual Health Care. 1996;8:
41-49.
11. Toy P. Guiding the decision to transfuse. Arch Pathol Lab Med.
1999;123:592-594.
